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Ifyou think you're too small to have an effect, you've never been in bed with a mosquito.
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Starving Tumors
Research conducted by a team ofCalifornia
scientists points the way to what ultimately
may become a promising cancer treatment:
a technique that triggers tumor regression
through the injection of one of two differ-
ent proteins. After injecting a single dose of
either a monoclonal antibody or a synthetic
protein into the vasculature surrounding
tumor fragments grafted onto chick
embryos, the scientists observed an
astounding result: the tumors not only
stopped growing, but they actually began
to decrease in size.
The experiments, led by cell biologists
Peter C. Brooks and David A. Cheresh at
San Diego's Scripps Institute, fall into an
area of cancer research called tumor angio-
genesis-the process by which a tumor
produces substances that support the de-
velopment of new blood vessels necessary
for tumor growth.
Their findings appear promising.
According to the study, published in the
30 December 1994 issue of Cell, the pro-
teins not only destroyed newly sprouting
blood vessels that nourished the growing
tumor but were also nontoxic to the sur-
rounding healthy tissue. While the re-
searchers don't claim to have found a cure
for cancer, they remain hopeful that their
research will have a positive impact on
human cancer treatment.
According to Brooks, research began
after his team made the initial observation
that a cell surface molecule, or integrin,
known as ccA was highly expressed in the
proliferating blood vessels around the
tumor, but not in the tumor itself. "In
order for a tumor to grow beyond one to
two millimeters, they required a blood sup-
ply," Brooks explains. "Instead oftargeting
the therapy to the tumor, we targeted it to
the vasculature around it." It's a novel
approach, since the other eight compounds
known to inhibit tumor angiogenesis-
now in clinical trials at research institutions
in the United States and Europe-are tar-
geted to affect the tumors themselves.
In their attempts to halt tumor growth,
the researchers targeted the ax 3 integrin,
which allows the cells lining the blood ves-
sels to attach to and interact with the
extracellular matrix. The genetically engi-
neered monoclonal antibody developed at
the Scripps Institute and a synthetic pep-
tide developed by E. Merck of Germany
both disrupt xvj3 function. The mono-
clonal antibody is licensed to Ixsys Inc., a
San Diego biotechnology company which,
according to Brooks, is planning to begin
clinical trials with the antibody (known as
LM609) on humans in 12-18 months.
In their study, Brooks and Cheresh
describe how the human body selectively
allows the development and destruction of
vascular cells. The av03 integrin sends out
a survival signal that normally would allow
maturation into a blood vessel. "The anti-
body and the peptide both block the trans-
mission ofsurvival signals to the endothe-
lial cells, leading to apoptosis, or pro-
grammed cell death," Brooks explains.
"The tumor also dies," he adds.
To observe the impact of the proteins
on tumor growth and survival, the scien-
tists planted tumor fragments onto 10-day-
old chick embryos, employing a classical
model for studying angiogenesis that was
pioneered by Judah Folkman, a veteran
angiogenesis researcher at the Harvard
Medical School. After several hours, new
blood vessels had begun to form in the
tumor fragments.
At the 24-hour mark, the scientists
introduced either of the two proteins to
some embryos, and allowed others to grow
without the proteins as a control. The
researchers observed a dramatically
Choking the flow. Blood vessels feeding human melanoma tumors (left) are disrupted by injection of
cyclic RGD peptides (right).
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reduced number of blood vessels feeding
the tumors in the embryos injected with
the proteins. The tumors actually regressed
and the embryos developed normally. In
the control embryos, the blood vessels pro-
liferated in their usual pattern, promoting
the growth ofthe tumors.
"The research is very promising and has
great potential," says James Pluda, an angio-
genesis expert at the National Cancer
Institute in Bethesda, Maryland. The exper-
iment designed by the Scripps researchers
"approaches disrupting the angiogenic path-
way at a point that is different than other
[studies have shown]," says Pluda.
"We're excited about having it
progress," says Pluda, who oversees the
development of anti-angiogenic drugs at
NCI. "It's very interesting; it's also very
preliminary," he cautions. The proteins
could lead to unwanted side effects in
other tissue, which could inhibit wound
healing, for example, or possibly lead to
fetal damage in pregnant women.
At this stage of research, scientists at
Ixsys are completing toxicology studies to
determine the extent, if any, of adverse
effects of the LM609 antibody. They will
also perform tests to rule out any biological
properties that would discourage the use of
the antibody in humans.
According to Brooks, the Scripps
research team duplicated their chick-
embryo test results in experiments on small
sections of human skin grafted onto mice
and observed a twofold reduction in tumor
size. Their laboratory findings held true for
a broad range of solid-tumor human can-
cers, including malignant melanomas and
cancers ofthe lung, breast, pancreas, brain,
and larynx.
According to Brooks, the team collabo-
rated with another Scripps researcher, oph-
thalmologist Martin Friedlander, and dis-
covered that the protein therapy may be
useful in treating several eye disorders as
well, including diabetic retinopathy and
macular degeneration.
Elusive EMFs
Do electric and magnetic fields (EMFs)
cause cancer? Researchers still don't know
for sure, since the latest epidemiological
look at EMF health effects contradicts
some previous findings.
The new study, conducted by epidemi-
ologist David A. Savitz ofthe University of
North Carolina-Chapel Hill School of
Public Health, underscores the need to
identify biological mechanisms associated
with EMF health effects, NIEHS officials
say.
Savitz, whose work in 1988 helped
spark intense public and scientific debate
over the safety of EMFs, now concedes
that future investiga-
tions must identify
"biologically relevant
exposure metrics." If
properly defined, he
adds, epidemiological
studies may still shed
light on EMF effects.
"I hate to give up
on epidemiology out-
right, but I think that
it needs to evolve," says
Savitz. "We need
either more innovative
epidemiological studies
or biological studies."
In his newly pub-
lished review of
138,905 male utility
workers, men exposed
to high-level 60-Hertz
magnetic fields were
about twice as likely to
develop brain cancer,
although they devel-
oped only about 70% as many brain
tumors as expected. Nonetheless, men sub-
jected to extremely high-level fields experi-
enced 2.6 times greater risk than the aver-
age American, Savitz reported with co-
author Dana Loomis in the American
JournalofEpidemiolog (vol. 141, no. 2).
Yet, Savitz found no link between mag-
netic fields and leukemia, except among
electricians. This finding is puzzling when
compared with other recent studies.
A 1993 report by J.D. Sahl and col-
leagues failed to identify any statistically
significant link between magnetic fields
and brain cancer or leukemia among
36,000 workers at the Southern California
Edison Company. Another study of
223,292 Canadian and French utility
workers, published in 1994 by Gilles
Theriault and associates, offered no con-
vincing evidence ofan increased brain-can-
cer risk among highly exposed groups.
Unlike Savitz, however, Theriault reported
that exposed individuals were up to three
times more likely to develop certain
leukemias.
Savitz was instrumental in launching
numerous epidemiological studies of EMF
effects. In 1988, he published a case-con-
trol study of 356 childhood cancer cases
whose findings seemed to confirm a 1979
study byepidemiologist NancyWertheimer
and physicist Ed Leeper. Among 344
Denver-area children, they reported, those
dwelling within 49 to 131 feet of high-
power electricity lines were two to three
times more likely to die ofcancers.
Despite 16 years of subsequent
research, however, the debate over EMFs
continues. In his latest study, Savitz care-
fully ruled out the effects of two other
Power thinker. David Savitz is among those researchers moving to mecha-
nistic studies of EMFs.
workplace carcinogens: polychlorinated
biphenyls (PCBs) and solvents. But he
could not account for many other variables
such as cigarette smoking among test sub-
jects or magnetic fields within homes.
Researcher Philip Cole of the
University of Alabama at Birmingham
questions Savitz's interpretation of the
EMF data. Among 138,905 workers, brain
cancer and nervous system cancers claimed
the lives of 151 men: 8 fewer deaths than
expected. In an unpublished evaluation of
the Savitz study, Cole says this finding is in
fact "negative, or at most weakly positive."
But Savitz says utility workers tend to be
healthier than the average American. "It's a
pretty well-established phenomenon that
working populations have lower mortalities
from a whole range ofcauses," he says.
Future studies must account for more
complex variables, says Wertheimer. Many
researchers believe that EMFs may work
cooperatively with other carcinogens to
promote tumor development, she notes.
Overall, the body of epidemiological
research thus far suggests a relatively small
increase in cancer risks (1.5 to 2.5 times
greater) for those exposed to high-level
magnetic fields, according to Savitz.
"Savitz has done the best job possible,"
Wertheimer continues. "But we still don't
know if [his test subjects] used electric
blankets or lived in high-exposure neigh-
borhoods. We still have avery blunt tool."
Attempts to hone that tool are being
made using toxicological and basic biologi-
cal studies as the focus of an EMF health
effects research program directed by the
NIEHS and administered by the U.S.
Department ofEnergy.
"It didn't make sense for us to fund
Volume 103, Number 5, May 1995 425